For research purposes only. Not for human consumption. For use by licensed researchers only.
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It has been studied extensively in preclinical and clinical research models for its potent effects on metabolic regulation, glycemic control, and body weight reduction.
Mechanism of Action
Tirzepatide activates both GIP and GLP-1 receptors simultaneously, producing synergistic effects on insulin secretion, glucagon suppression, and gastric emptying. Research indicates the dual agonism leads to superior glycemic control and weight loss compared to single receptor agonism, with GIP receptor activation also believed to modulate adipose tissue metabolism and energy expenditure.
Research Applications
- Type 2 diabetes and glycemic regulation research
- Obesity and body weight management models
- Dual incretin receptor signaling studies
- Cardiovascular metabolic risk factor research
- Insulin secretion and pancreatic beta-cell function studies
Research Grade Peptide
| Compound | Tirzepatide (Dual GIP/GLP-1 Receptor Agonist) |
| Strength | 10 mg |
| Vial Size | 3 mL |
| Vial Color | Clear |
| Form | Lyophilized Powder |
| Purity | >98% (HPLC verified) |
| Price | $129.00 |
This compound is provided strictly for in vitro and laboratory research. It has not been evaluated by the FDA and is not intended for diagnostic, therapeutic, or human use. Available to licensed researchers only.